Paul Joseph Piazza is a pharmacist who is specialized in Oncology in Bridgeport, Connecticut. Patients can reach him at 267 Grant St, Bridgeport or contact him on 203-384-3252. Active license number of Paul Joseph Piazza is 0007884 for Oncology in Connecticut. Paul Joseph Piazza is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Paul Joseph Piazza speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Paul Joseph Piazza
Specialization:
Oncology
Gender:
Male
Location:
267 Grant St, Bridgeport, Connecticut, 06610-2870
Phone:
203-384-3252
Fax:
203-384-3625
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Paul Joseph Piazza are as mentioned below.
NPI Number:
1033778691
NPI Enumeration Date:
07 Jun, 2019
NPI Last Update On:
07 Jun, 2019
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Paul Joseph Piazza are as mentioned below.
Specialization
License Number
State
Status
Oncology
0007884
Connecticut
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
267 Grant St, Bridgeport, Connecticut
Zip:
06610-2870
Phone Number:
203-384-3252
Fax Number:
203-384-3625
Patients can reach Paul Joseph Piazza at 267 Grant St, Bridgeport, Connecticut or can call on phone at 203-384-3252.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.